ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1698 • ACR Convergence 2022

    LINE1 Reverse Transcriptase Inhibitors Abrogate Type 1 Interferon Responses

    Daniel Rios1, Nafeeza Hafeez1, Brian Desrosiers1, Shradha Rao1, Jess Floro1, Joelle Baddour1, Nisha Perez2, Greg Bisacchi2, Oliver Saunders2, Donna Romero1, Menachem Fromer2, Enrique Garcia-Rivera2, Wilson McKerrow2, Julie Behr2, Bryan Thornlow2, Dennis Zaller2, David Proia2 and Wenyan Miao2, 1Rome Therapeutics, Cambridge, MA, 2Rome Tx, Cambridge, MA

    Background/Purpose: Transposable elements (TEs) are mobile DNA elements that can replicate and move from one position to another within the host genome. Through co-evolution, TEs…
  • Abstract Number: 1713 • ACR Convergence 2022

    Bank1 Signaling Shapes the Gut Microbiota Composition by Controlling the Gut Mucosal B-cell Response in Lupus

    Georgina Galicia-Rosas, María Botía Sánchez, Daniel Toro-Domínguez, Lorena Albadalejo and Marta Alarcon-Riquelme, Center for Genomics and Oncological Research (GENYO), Granada, Spain

    Background/Purpose: Mucosa-associated commensal bacteria have been shown to be involved in the pathogenesis of systemic lupus erythematosus (SLE). However, its exact role remains to be…
  • Abstract Number: 1714 • ACR Convergence 2022

    The Circadian Clock Gene Bmal1 Negatively Regulates Autoantibody Production in SLE

    Shuichiro Nakabo1, Donavon Sandoval-Heglund1, Victoria Hoffmann2, Mingzeng Zhang1, Norio Hanata1, Zerai Manna1, Elaine Poncio1, Sarfaraz Hasni3 and Mariana Kaplan4, 1NIAMS/NIH, Bethesda, MD, 2ORS/ORF/NIH, Bethesda, MD, 3National Institutes of Health, Bethesda, MD, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD

    Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that affects multiple organs including kidney and skin. While its etiology and pathogenesis are still…
  • Abstract Number: 1717 • ACR Convergence 2022

    Deficiency of IL-23 Receptor in Podocytes of MRL/lpr lupus-prone Mice Abrogates the Development of Lupus Nephritis Despite IgG Deposition in the Glomeruli

    Afroditi Boulougoura1, Hao Li1, Rhea Bhargava1, Wenliang Pan1, Abhigyan Satyam1, Isaac Stillman2 and George Tsokos1, 1Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 2Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

    Background/Purpose: Interleukin 23 (IL-23) is involved in the pathogenesis of systemic lupus erythematosus (SLE). IL-23 is elevated in the sera of patients with active SLE…
  • Abstract Number: 1716 • ACR Convergence 2022

    The Transcriptomic Landscape of Nephritic Kidneys Reveals Mechanisms for End Organ Resistance to Damage in Lupus-prone Mice

    Andrea Daamen1, Hongyang Wang2, Prathyusha Bachali3, Shu Man Fu2, Amrie Grammer4 and Peter Lipsky1, 1AMPEL BioSolutions, Charlottesville, VA, 2University of Virginia, Charlottesville, VA, 3AMPEL BioSolutions, Redmond, WA, 4AMPEL LLC, Charlottesville, VA

    Background/Purpose: Pathologic inflammation is a major driver of kidney damage in lupus nephritis (LN), but the immune mechanisms of disease progression and risk factors for…
  • Abstract Number: 1718 • ACR Convergence 2022

    Parenchymal INFγ Response Regulates Murine Lupus Nephritis

    Minjung Kim1, Anthony Marinov1, Mark Shlomchik2 and Jeremy Tilstra2, 1University of Pittsburgh, Pittsburgh, 2University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Lupus nephritis is the most common life-threatening end-organ complication of SLE. Interstitial infiltrates, specifically T cells, are major predictors of disease outcomes. We recently…
  • Abstract Number: 1715 • ACR Convergence 2022

    Ezh2 Knockout in B Cells Impairs Plasmablast Differentiation and Ameliorates Lupus-like Disease in MRL/lpr Mice

    Xiaoqing Zheng1, Mikhail Dozmorov2, Colleen Strohlein1, Sheldon Bastacky1 and Amr Sawalha1, 1University of Pittsburgh, Pittsburgh, PA, 2Virginia Commonwealth University, Richmond, VA

    Background/Purpose: Enhancer of zeste homolog 2 (EZH2) has been shown to regulate early B cell development and the differentiation of antibody secreting cells (ASCs). We…
  • Abstract Number: 1696 • ACR Convergence 2022

    Single Cell RNA-seq Identifies Major Shifts in Myeloid Cells in Dermatomyositis Skin and Peripheral Blood Compared to Systemic Lupus

    Grace Hile, Feiyang Ma, Amanda Victory, Bin Xu, Mehrnaz Gharaee-Kermani, Elisabeth Pedersen, Rachael Wasikowski, Celine Berthier, Vladimir Ognenovski, Allison Billi, Johann Gudjonsson and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI

    Background/Purpose: Skin disease in dermatomyositis (DM) is relapsing and often refractory to treatment, reflecting a lack of understanding of the mechanisms driving skin inflammation. DM…
  • Abstract Number: 1721 • ACR Convergence 2022

    Protective Effects of the Natural Antioxidant Taxifolin in Models of Lupus and Antiphospholipid Syndrome

    Christine Rysenga1, Linda May-Zhang2, Miela Zahavi3, Jason S Knight4 and Ramadan Ali1, 1University of Michigan, Ann Arbor, MI, 2Blue California, Rancho Santa Margarita, CA, 3Universtiy of Michigan, Ann Arbor, MI, 4University of Michigan, Division of Rheumatology, Ann Arbor, MI

    Background/Purpose: Taxifolin, also known as dihydroquercetin, is a bioactive flavonoid commonly found in apples, onions, French maritime bark, and milk thistle. Given its potent anti-inflammatory…
  • Abstract Number: 1722 • ACR Convergence 2022

    The ERβ Agonist, WT-IV-012, Suppresses the Inflammatory Response in Systemic Lupus Erythematosus

    Shane Bruckner1, Braden Zeno1, William Willis2, Chad Bennett1 and Wael Jarjour1, 1The Ohio State University, Columbus, OH, 2Ohio State, Reynoldsburg, OH

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple organ damage, mainly affecting young women between the ages of 15 and 45…
  • Abstract Number: 1724 • ACR Convergence 2022

    Perivascular Adipose Tissue Promotes Vascular Dysfunction in Murine Lupus

    Hong Shi1, Brandee Goo2, David Kim2, Taylor Kress2, Eric Belin de Chantemele2, Xiaochun Long2, Ha Won Kim2, Laura Carbone3, Brian Annex4 and Neal Weintraub4, 1Department of Internal Medicine/Division of Rheumatology, Vascular Biology Center, Augusta, GA, 2Vascular Biology Center, Augusta, GA, 3Augusta University, Augusta, GA, 4Department of Internal Medicine/Division of Cardiology, Vascular Biology Center, Augusta, GA

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at high risk for cardiovascular disease (CVD) due to accelerated atherosclerosis. lupus patients have more thoracic perivascular…
  • Abstract Number: 1725 • ACR Convergence 2022

    Sex Differences in Autoimmune Pathogenesis and Systemic Response to High Fat Diet in Lupus-prone Mice

    Gitanjali Lobo1, Juan Meng2, Xuhua Shi2, Ronak Patel3, Laura Rivers4, Chad Hille5, Robert Quinet6, William Davis7, Jerald Zakem8, Chandana Keshavamurthy9, Tamika Webb-Detiege10, Zongbing You2 and Xin Zhang11, 1Ochsner Clinic Foundation, Metairie, LA, 2Tulane University, New Orleans, LA, 3Ochsner, New Orleans, LA, 4Ochsner Medical Center, River Ridge, LA, 5Ochsner Clinic Foundation, New Orleans, LA, 6Ochsner Health, River Ridge, LA, 7Ochsner Medical Center, New Orleans, LA, 8Ochsner Health Systems, Metairie, LA, 9ochsner medical center, Metairie, LA, 10University of Queensland/Ochsner Clinical School, New Orleans, LA, 11Institution of Translational Research, Ochsner Health System, New Orleans, LA

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by chronic inflammation and the production of autoantibodies, leading to systemic multiorgan damage. SLE has…
  • Abstract Number: 1720 • ACR Convergence 2022

    FASlpr Gene Dosage Differentiates Lymphoproliferative from Non-lymphoproliferative Autoimmunity – a Novel Mouse Model of Lupus

    Ritu Bohat1, Chunyu Xu1, Xiaofang Liang1, Yanping Chen1, Ningbo Zheng1, Roshni Jaffery1, Ashley Guerrero1, Nicholas Egan1, John Hicks2, Chandra mohan1 and Weiyi Peng1, 1University of Houston, Houston, TX, 2Baylor College of Medicine, Houston, TX

    Background/Purpose: Sle1 and FASlpr are two lupus susceptibility loci that lead to manifestations of systemic lupus erythematosus (SLE) by altering the FAS/FASL pathway and adaptive…
  • Abstract Number: 1699 • ACR Convergence 2022

    Arthritis-associated Synovial CD64-Ly6c- myeloid Cells Comprise 2 Subpopulations

    Yidan Wang1, Miranda Gurra1, Carla Cuda1, Hadijat Makinde1, Shangyang Chen1, Gaurav Gadhvi1, Salina Dominguez1, Caroline Shah1, Deborah Winter2 and Harris Perlman1, 1Northwestern University, Chicago, IL, 2Northwestern University, Skokie, IL

    Background/Purpose: Monocytes are critical for the pathogenesis of rheumatoid arthritis (RA). However, depletion of circulating monocytes – either classical or non-classical monocytes – is not…
  • Abstract Number: 1731 • ACR Convergence 2022

    Systemic Sclerosis-Associated Class II HLA Alleles Restrict the Diversity of the CDR3 and the T Cell Receptor Repertoire in African American Patients

    Urvashi Kaundal1, Chloe Borden1, Cihan Oguz2, Jinghua Lu2, Emilee Stenson1, Ami Shah3, Maureen Mayes4, Ayo Doumatey5, Amy Bentley5, Daniel Shriner5, Robyn Domsic6, Thomas Medsger7, Paula Ramos8, Richard Silver8, Virginia Steen9, John Varga10, Vivien Hsu11, Lesley Ann Saketkoo12, Elena Schiopu13, Dinesh Khanna14, Jessica Gordon15, Lindsey Criswell16, Heather Gladue17, Chris Derk18, Elana Bernstein19, S. Louis Bridges, Jr.15, Victoria Shanmugam20, Lorinda Chung21, Suzanne Kafaja22, Reem Jan23, Marcin Trojanowski24, Avram Goldberg25, Benjamin Korman26, Settara Chandrasekharappa5, Faiza Naz27, Stefania Dell'Orso1, Adebowale Adeyemo5, Charles Rotimi5, Elaine Remmers5, Francesco Boin28, Fredrick Wigley29, Peter Sun2, Daniel Kastner5 and Pravitt Gourh30, 1National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 2National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 3Johns Hopkins Rheumatology, Baltimore, MD, 4Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, 5National Human Genome Research Institute, Bethesda, MD, 6University of Pittsburgh, Pittsburgh, PA, 7University of Pittsburgh School of Medicine, Pittsburgh, PA, 8Medical University of South Carolina, Charleston, SC, 9Georgetown University School of Medicine, Washington, DC, 10University of Michigan, Ann Arbor, MI, 11Rutgers-RWJ Medical School, South Plainfield, NJ, 12University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris, New Orleans, LA, 13Michigan Medicine, Ann Arbor, MI, 14Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, 15Hospital for Special Surgery, New York, NY, 16National Human Genome Research Institute, NIH, Bethesda, MD, 17Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, 18University of Pennsylvania, Philadelphia, PA, 19Columbia University, New York, NY, 20George Washington University, Great Falls, VA, 21Stanford University, Stanford, CA, 22UCLA Department of Medicine, Division of Rheumatology, Los Angeles, CA, 23University of Chicago, Chicago, IL, 24Boston University School of Medicine, Boston, MA, 25NYU Langone Medical Center - NYU Hospital for Joint Diseases, Lake Success, NY, 26University of Rochester, Rochester, NY, 27National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 28Cedars-Sinai Medical Center, Los Angeles, CA, 29Johns Hopkins University, Baltimore, MD, 30National Institutes of Health, Bethesda, MD

    Background/Purpose: Systemic sclerosis (SSc) is an autoimmune, fibrotic disorder that disproportionately affects African Americans (AA). Previous work from our lab and others has suggested a…
  • « Previous Page
  • 1
  • …
  • 656
  • 657
  • 658
  • 659
  • 660
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology